Gsa Capital Partners LLP Cure Vac N.V. Transaction History
Gsa Capital Partners LLP
- $1.11 Billion
- Q1 2025
A detailed history of Gsa Capital Partners LLP transactions in Cure Vac N.V. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 307,941 shares of CVAC stock, worth $1.06 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
307,941Holding current value
$1.06 Million% of portfolio
0.08%Shares
2 transactions
Others Institutions Holding CVAC
# of Institutions
93Shares Held
10.6MCall Options Held
75.1KPut Options Held
86.7K-
Black Rock Inc. New York, NY2.25MShares$7.73 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.82MShares$6.23 Million0.0% of portfolio
-
Bill & Melinda Gates Foundation Seattle, WA1.57MShares$5.38 Million10.6% of portfolio
-
Ubs Group Ag843KShares$2.89 Million0.0% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL277KShares$948,4120.0% of portfolio
About CureVac N.V.
- Ticker CVAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,467,008
- Market Cap $643M
- Description
- CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...